PeptideComparePNC-27 — EU research guide.
PNC-27 is a chimeric peptide containing an HDM-2-binding domain linked to a transmembrane-penetrating peptide. It selectively disrupts the membranes of cancer cells expressing HDM-2 while leaving normal cells intact.
What is PNC-27?
PNC-27 was developed by Matthew Pincus and colleagues at SUNY Downstate. It consists of a p53 residue 12–26 sequence (which binds HDM-2) fused to a membrane-disrupting leader peptide. Cancer cells overexpressing HDM-2 on their surface are selectively lysed; normal cells lacking surface HDM-2 are spared. The mechanism is membrane disruption, not apoptosis signalling.
What does the research show?
In vitro studies show selective killing of HDM-2-expressing cancer cell lines (pancreatic, breast, leukaemia) with no toxicity to normal cells. Animal model data is limited. No human clinical trials have been conducted. PNC-27 represents early-stage oncology research with a novel mechanism of selectivity.
EU legal status
PNC-27 is purely a research compound with no clinical development history beyond laboratory studies. It is available for in-vitro oncology research only. Not for human use under any circumstances.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
PNC-27 across EU suppliers
COA-verified EU vendors · Updated monthly